All In MedTech

Device Trial Radar · NCT05766488

Assessing Continuous Glucose Monitor Use in Underserved Primary Care Patients

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jul 23, 2023

Primary completion

Jul 20, 2026

Study completion Jul 20, 2026

Sponsor

Lead sponsor
University of NebraskaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Great Plains IDeA-CTR
First posted
Mar 13, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Continuous glucose monitoring (CGM) has demonstrated improved outcomes in both type 1 and type 2 diabetes populations in comparison to traditional methods; however, these devices have not been well studied in underserved adult patients (e.g., low-income, uninsured) who may face additional barriers to monitoring. Furthermore, there is limited data exploring long-term (3- to 6- month) health care team-based management of these devices in the primary care setting. The purpose of this study is to further understand the benefits and barriers associated with CGM use in underserved populations with type 2 diabetes and improve their overall diabetes care.

Conditions

  • Type 2 Diabetes

Interventions

  • Continuous Glucose Monitor (CGM)Device

    A Freestyle Libre 2 continuous glucose monitor (CGM) will be provided in the experimental arm of this study for 6 months.

  • Self-monitoring Blood Glucose (SMBG)Device

    A traditional glucometer device will be assigned in the active comparitor arm of this study for 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glycemic Control (Hemoglobin A1c)Time frame: Baseline, 3 months, and 6 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nebraska Medicine

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.